The Imperative for High-Quality Control in Biomanufacturing In the ever-evolving landscape of biopharmaceutical manufacturing, the imperative for maintaining high-quality control measures is unarguable. With the introduction of complex biological materials into gene therapies and vaccine
At the recent BPI Europe 2024 conference, a landmark discussion led by Uwe Buecheler from Boehringer Ingelheim marked the dawn of a new chapter in biopharmaceuticals. Described as the 'third wave' of biologics, it signifies an era brimming with groundbreaking therapeutic innovations that stand to
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is heralding a new era in biopharmaceutical production with a significant investment that aims to spur innovation and streamline processes in this critical industry. In its latest move, NIIMBL has dedicated $10
